Nanoparticle vax cures Type 1 diabetes in mice

In a study co-funded by the Juvenile Diabetes Research Foundation, researchers at the University of Calgary were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. Using a sophisticated, nanotechnology-based “vaccine,” Dr. Pere Santamaria, Chair of the Julia McFarlane Diabetes Researcher Centre in UCalgary’s Faculty of Medicine and his team were able to specifically stop the autoimmune response that causes type 1 diabetes without damaging the immune cells that provide protection against infections. Dr. Santamaria notes that “if the paradigm on which this nanovaccine is based holds true in other chronic autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and others, nanovaccines might find general applicability in autoimmunity,"

- read this article for more

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.